**Name of Journal:** *World Journal of Gastrointestinal Oncology*

**Manuscript NO:** 82372

**Manuscript Type:** ORIGINAL ARTICLE

***Basic Study***

**Possible mechanisms associated with immune escape and apoptosis on anti-hepatocellular carcinoma effect of Mu Ji Fang granules**

Zhang YB *et al*. MJF on anti-hepatocellular carcinoma

Yi-Bing Zhang, Yong-Rui Bao, Shuai Wang, Tian-Jiao Li, He Tai, Jia-Peng Leng, Xin-Xin Yang, Bo-Cai Wang, Xian-Sheng Meng

**Yi-Bing Zhang, Yong-Rui Bao, Shuai Wang, Tian-Jiao Li, He Tai, Jia-Peng Leng, Xin-Xin Yang, Bo-Cai Wang, Xian-Sheng Meng,** College of Pharmacy, Liaoning University of Traditional Chinese Medicine, Dalian 116600, Liaoning Province, China

**Yi-Bing Zhang,** Department of Clinical Trail Institution Office, Dalian Municipal Central Hospital, Dalian 116033, Liaoning Province, China

**Yong-Rui Bao, Shuai Wang, Tian-Jiao Li, Xian-Sheng Meng,** Technical Innovation Center of Multidimensional Analysis of Traditional Chinese Medicine of Liaoning Province, Dalian 116600, Liaoning Province, China

**Yong-Rui Bao, Shuai Wang, Tian-Jiao Li, Xian-Sheng Meng,** Engineering Laboratory of Modern Chinese Medicine Research of Liaoning Province, Dalian 116600, Liaoning Province, China

**Author contributions:** Zhang YB, Bao YR, Wang S, Wang BC and Meng XS contributed to conception and design of the study; Zhang YB, Wang S, Li TJ, Tai H, Leng JP, Wang BC and Yang XX conducted the experiments, organized the database, carried out the statistical analysis and drafted the manuscript; All authors contributed to manuscript revision, and approved the submitted version.

**Supported by** National Natural Science Foundation of China, No. 81874342; and Natural Science Foundation of Liaoning Province, No. 2020-MZLH-35.

**Corresponding author: Xian-Sheng Meng, PhD, Dean, Professor,** College of Pharmacy, Liaoning University of Traditional Chinese Medicine, No. 77 Life one Road, DD Port, Jinpu District, Dalian 116600, Liaoning Province, China. mxsvvv@163.com

**Received:** December 20, 2022

**Revised:** January 19, 2023

**Accepted:** March 2, 2023

**Published online:**

**Abstract**

BACKGROUND

Hepatocellular carcinoma (HCC) is one of the most common digestive system cancers with high mortality rates worldwide. The main ingredients in Mu Ji Fang Granules (MJF) are alkaloids, flavonoids, and polysaccharides. MJF has been used in the clinical treatment of hepatitis, cirrhosis and HCC for more than 30 years. Few previous studies have focused on the mechanism of MJF on tumor immunology in the treatment of HCC.

AIM

To explore the mechanism of action of MJF on tumor immunology in the treatment of HCC.

METHODS

The absorbable ingredients of MJF were identified using Molecule Network related to High Performance Liquid Chromatography-Electron Spray Ionization-Time of Flight- Mass Spectrometry, and hub potential anti-HCC targets were screened using network pharmacology and pathway enrichment analysis. Forty male mice were randomly divided into the Blank, Model, and MJF groups (1.8, 5.4, and 10.8 g/kg/d) following 7 d of oral administration. Average body weight gain, spleen and thymus indices were calculated, tumor tissues were stained with hematoxylin and eosin, and Interferon gamma (IFN-γ), Tumor necrosis factor α (TNF-α), Interleukin-2, aspartate aminotransferase, alanine aminotransferase, alpha-fetoprotein (AFP), Fas, and FasL were measured by Enzyme-linked Immunosorbent Assay. Relevant mRNA expression of *Bax* and *Bcl2* was evaluated by Real Time Quantitative PCR (RT-qPCR) and protein expression of Transforming growth factor β1 (TGF-β1) and Mothers against decapentaplegic homolog (SMAD) 4 was assessed by Western blotting. The HepG2 cell line was treated with 10 mg/mL, 20 mg/mL, 30 mg/mL, 40 mg/mL of MJF, and another 3 groups were treated with TGF-β1 inhibitor (LY364947) and different doses of MJF. Relevant mRNA expression of TNF-α, IFN-γ, *Bax* and *Bcl2* was evaluated by RT-qPCR and protein expression of TGF-β1, SMAD2, p-SMAD2, SMAD4, and SMAD7 was assessed by Western blotting.

RESULTS

It was shown that MJF improved body weight gain and tumor inhibition rate in H22 tumor-bearing mice, protected immune organs and liver function, reduced the HCC indicator AFP, affected immunity and apoptosis, and up-regulated the TGF-β1/SMAD signaling pathway, by increasing the relative expression of TGF-β1, SMAD2, p-SMAD2 and SMAD4 and decreasing SMAD7, reducing immune factors TNF-α and IFN-γ, decreasing apoptosis cytokines Fas, FasL and *Bcl2*/*Bax*, and inhibiting the effect of LY364947 in HepG2 cells.

CONCLUSION

MJF inhibits HCC by activating the TGF-β1/SMAD signaling pathway, and affecting immune and apoptotic cytokines, which may be due to MJF adjusting immune escape and apoptosis.

**Key Words:** Mu Ji Fang granules; Hepatocellular carcinoma; Transforming growth factor β1/Mothers against decapentaplegic homolog; Immune escape; H22 tumor-bearing mice; HepG2 cells

Zhang YB, Bao YR, Wang S, Li TJ, Tai H, Leng JP, Yang XX, Wang BC, Meng XS. Possible mechanisms associated with immune escape and apoptosis on anti-hepatocellular carcinoma effect of Mu Ji Fang granules. *World J Gastrointest Oncol* 2023; In press

**Core Tip:** Mu Ji Fang Granules (MJF), a Chinese patent medicine, has been used in hepatitis, cirrhosis and hepatocellular carcinoma (HCC) for more than 30 years. MJF was identified with Molecule Network related to High Performance Liquid Chromatography-Electron Spray Ionization-Time of Flight- Mass Spectrometry, and hub potential anti-HCC targets were screened using network pharmacology and pathway enrichment analysis in H22 tumor-bearing mice and HepG2 cells. It was shown that MJF improved body weight gain and tumor inhibition rate, protected immune organs and liver function, affected immunity and apoptosis, up-regulated the Transforming growth factor β1(TGF-β1)/ Mothers against decapentaplegic homolog(SMAD) signaling pathway, and inhibited the effect of TGF-β1 inhibitor (LY364947).

**INTRODUCTION**

In the World Health Organization 2018 World Cancer Report, liver cancer is the sixth most common cancer and the fourth most common cause of cancer death worldwide, and the age-standardized rates in Asia and Africa were 2 to 3 times those in America, Europe, and Oceania[1]. In the latest report on cancer epidemiology in China, liver cancer was the third and seventh most common malignancy in males and females, with an incidence rate of 12.74% and 5.40%, and the second and third highest mortality rate of 16.36% and 9.79%, respectively[2].

Mu Ji Fang granules (MJF, also known as Fufang Mu Ji Granules), a Chinese patent medicine produced by Dandong Pharmaceutical Group Co., Ltd (Liaoning, China), derived from a folk prescription of the Manchu medicine, consists of 4 herbs including Sophorae Tonkinensis Radix[3], Cuscutae Semen[4], Juglans mandshurica Maxim[5] and Coriolus versicolor[6] (Table 1), processed into proprietary Chinese medicine, has been used in patients with hepatitis, cirrhosis and hepatocellular carcinoma (HCC) for many years and has a considerable curative effect in clinical practice[7]. Previous studies of MJF mainly focused on its clinical efficacy in hepatitis B[8,9] and fundamental pharmacological effects[10], but few reported the mechanism of action on tumor immunology in the treatment of HCC. Our research group previously established the High Performance Liquid Chromatography (HPLC) fingerprint chromatogram of MJF, combined with HPLC-Electron Spray Ionization-Time of Flight- Mass Spectrometry(HPLC-ESI-TOF-MS), and identified the main compounds in MJF to be alkaloids, flavonoids, and polysaccharides. Based on these findings we hypothesize that MJF might be able to promote tumor cell apoptosis, anti-inflammatory activity and enhance immunity.

In this study, we used Molecule Network (MN) coupled with UPLC-ESI-TOF-MS to analyze the compounds in mouse plasma and a chemical profile was built based on the structures of these compounds. Combined with the compounds from MN, network pharmacology was adopted to analyze the anti-HCC pharmacological mechanisms of MJF. H22 tumor-bearing mice and HepG2 cells were introduced as experimental support for verification, Enzyme Linked Immunosorbent Assay (ELISA), Real Time Quantitative PCR (RT-qPCR), and Western blotting assays were used to evaluate the expression levels of target genes *in vivo* and *in vitro*. Our data indicated that MJF had an anti-HCC effect by regulating immune escape and promoting apoptosis.

**MATERIALS AND METHODS**

***Establishment of H22 tumor-bearing mouse models and sample preparation***

Eight-week-old Institute of Cancer Research (ICR) male mice weighing 18-22 g, (Experimental Animal Center of Liaoning Changsheng Biological Technology Co., Ltd., License No. SCXK Liao 2015-0001), were adaptively raised in a controlled-environment animal experiment room (temperature 20°C-25°C, humidity 45%-65%, light / dark cycle for 12 h / 12 h) for 7 d with free access to food and tap water. All experimental procedures were performed with the approval of the animal guidelines and protocols established by the Medicine Ethics Review Committee of Animal Experiments of Liaoning University of Traditional Chinese Medicine (TCM) and The Affiliated Hospital of Liaoning University of TCM. Mouse HCC H22 cell strain (Jiangsu Chi Scientific Co., Ltd.) was cultured in RPMI-1640 culture medium (Gibco, Thermo Fisher Scientific, Waltham, MA, United States) containing 1% streptomycin and 10% fetal bovine serum (100 μg/mL penicillin, 100 μg/mL streptomycin) (Gibco Inc. United States) in an incubator at 37 °C, 5% CO2 and 95% of relative saturation humidity. H22 cells in the logarithmic growth period were adjusted to 1 × 107/mL with saline for intraperitoneal injection into mice at 0.2 mL each animal. Five days later, the mice developed ascites due to the growth of H22 cells in the abdominal cavity. We extracted abdominal ascites from the mice and adjusted them to 1 × 107/mL with saline as the first generation ascites and repeated the above intraperitoneal injection twice in healthy mice. The third generation ascites were harvested and adjusted to 1 × 107/mL with saline as the final implant cell line. An axillary vaccination was conducted in each mouse using 0.2 mL H22 diluted ascites. Three days later, nodules were observed in the right armpit of the mouse, indicating that the established model was successful.

Forty mice were randomly divided into the Model group, cyclophosphamide (CTX) group (cyclophosphamide, 2.7 mg/mL), and 3 MJF groups (M-L received a low MJF dose of 1.8 g/kg, M-M received a mid MJF dose of 5.4 g/kg, M-H received a high MJF dose of 10.8 g/kg) with 8 mice in each group. A further 8 ICR male mice (weighing 18-22 g) were included in the Blank group. All mice were administered the drugs orally once a day (the Blank and Model groups received saline) for 7 d, no food was allowed 12 h before the experiment, but the animals had free access to water. Thirty minutes after the final drug administration, all mice were euthanized under deep anesthesia. Body weight was measured and blood was collected for analysis. After sacrifice, intact thymus, spleen, and tumor tissues were removed and weighed (Figure 1). The thymus index, spleen index, and tumor inhibitory rates in each mouse were calculated according to the following formulas.

Thymus index = thymus weight (mg)/ body weight (g) × 10

Spleen index = spleen weight (mg)/ body weight (g) × 10

Tumor inhibitory rate (%) = (1 - average tumor weight in the drug administration group/ average tumor weight in the Model group) × 100%

***Drug and plasma sample preparation for HPLC-ESI-TOF-MS and ingredient identification***

Five gram MJF granules (# 20190725334, provided by Dandong Pharmaceutical Group Co., Ltd., Dandong China) were weighed and added to 30 mL anhydrous methanol (HPLC grade, Merck Co. Ltd., Darmstadt, Germany), ultrasonically extracted for 30 min, and then filtered through a micropore membrane (0.22 mm; Jinteng Corp., Tianjin, China) before use. Seventeen accurately weighed reference substances were mixed and dissolved in 10 mL of methanol to obtain a solution at the concentration of 21.00 μg/mL for protocatechuic acid, 24.54 μg/mL for ellagic acid, 18.96 μg/mL for kaempferol-3-O-rutinoside, 17.45 μg/mL for rutin, 15.09 μg/mL for hyperoside, 20.64 μg/mL for isoquercitrin, 18.44 μg/mL for astragalin, 17.42 μg/mL for kaempferol, 18.40 μg/mL for isorhamnetin, 20.62 μg/mL for marine, 23.36 μg/mL for sophocarpine, 18.43 μg/mL for gallic acid, 16.48 μg/mL for naringenin, 22.72 μg/mL for cytisine, 21.53 μg/mL for caffeate, 21.34 μg/mL for quercetin (Sichuan Victory Biological Technology Co., Ltd., Sichuan, China) and 18.92 μg/mL for ferulic acid (HPLC grade, Tianjin Kermel Chemical Co., Tianjin, China). 50 μL of thawed frozen plasma samples of MJF high dose (M-H) were placed into 1 mL centrifuge tubes, and then thoroughly mixed with 100 μL methanol and vortexed for 1 min. The solutions were centrifuged at 8000 rpm/min and 4 °C for 10 min. The supernatants were filtered through a 0.22 μm membrane for HPLC-MS analyses.

The HPLC–MS analysis was performed using an Agilent 1290 HPLC system (Agilent Technologies, Inc., CA, United States) in tandem with an Agilent 6550 quadrupole-time of flight with mass spectrometry (Agilent Co., United States). The analysis system consisted of an Agilent Proshell SB-C18 column (100 mm × 3 mm, 2.1 μm) (Agilent Technologies, Inc., CA, United States) and was used with the column temperature maintained at 35 °C; the flow rate of the mobile phase was 0.4 mL/min and the injection volume was 0.6 μL, the mobile phase consisted at 0.1% formic acid in water of A and acetonitrile of B, and the column was eluted with a linear gradient of 3%–8% B over initial to 5.0 min, 8%–15% B over 5.0-9.0 min, 15%-22% B over 9.0-12.0 min, 22%-55% B over 12-15 min, 55%-70% over 15-20 min,70%–95% B over 20.0–24.0 min, returned to 3% B for 1.0 min and then held for 2.5 min at an eluent flow rate of 0.5 mL/min. Optimal conditions for HPLC-Q-TOF-MS analysis were as follows: ion source was Dual AJS ESI, both positive and negative ion mode detection was adopted, drying gas flow of 13 L/min, drying gas temperature maintained at 350 °C, a capillary voltage of 3500 V, nebulizer pressure of 310.28 kPa, frag mentor voltage of 125 V, OCT 1RF Vpp voltage of 750 V, collision energy of 40 eV and mass spectrometric data were acquired in the mode from 1000 to 1000 m/z with an acquisition rate of 1.5 spectra/s. Data were corrected and obtained during acquisition using a correction mixed solution (Agilent Technologies, Inc., CA, United States, m/z = 112.985587, m/z = 1033.988109).

***Molecular networking establishment of MJF and the identification of absorbable ingredients***

For MN data processing, MS/MS data on MJF extraction and MJF high dose were collected and converted into mzXML format using Proteo Wizard software (www.proteowizard.sourceforge.net, Proteo Wizard, Palo Alto, CA, United States) and then uploaded separately into the GNPS platform (<https://gnps.ucsd.edu>, UCSD, San Diego, CA, United States) (accessed on 16 November 2021) (Figure 2A). The GNPS parameters were as follows: mass error of less than 0.02 Da, matched peaks greater than 3, and cosine score greater than 0.50. After analysis, graphic format files were generated from the GNPS platform, and the files were then downloaded and imported into Cytoscape software v 3.7.0 (www.cytoscape.org, NRNB, Hill St, San Diego, CA, United States) to build the molecular network. According to Wang *et al*’s study[11], MN of MJF extraction and plasma after MJF oral administration were merged, and the absorbed constituents of MJF in plasma were obtained. All constituents were identified using reference substances on HPLC-Q-TOF-MS.

***Network pharmacology construction and pathway enrichment analysis of MJF***

One thousand two hundred and thirty-two HCC-related genes were extracted from DisGeNET[12] (https://www.disgenet.org) and two liver cancer databases Liverome[13] (http://Liverome.kobic.re.kr/index.php) and OncoDB. HCC[14] (http://oncodb.hcc.ibms.sinica.edu.tw). Validated and predicted targets of 17 ingredients screened from MN of MJF were collected from Swiss Target Prediction[15] (http://www.swisstargetprediction.ch), an online tool to predict the macromolecular targets (proteins from human, mouse, and rats) of small bioactive molecules. All the ingredient-related genes were mapped to HCC-related genes to obtain a total of 221 shared targets, which were then uploaded to the STRING database[16] (https://string-db.org) to acquire the protein-protein interaction (PPI) network. Cytoscape software and the Network Analyzer App were employed for topological analysis of the PPI network, and the medians of each index were calculated. Nodes of a degree over 19, betweenness centrality over 0.00283, and closeness centrality over 0.51485 were gathered as predicted targets and were uploaded to the Metascape database[17] (https://metascape.org/) for possible Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways enrichment. The final results of the ingredient-pathway-target network were demonstrated by Cytoscape.

***Histopathological analysis and biochemical analysis***

Mouse tumor tissues were immediately fixed in 4% paraformaldehyde (Beijing Solaibao Technology Co., Ltd., Beijing, China). Following paraffin embedding, the tissues were cut into 4 μm slices, stained with hematoxylin and eosin (HE), and morphological changes were observed with a microscope (× 200 high power visual field).

Plasma samples from all five groups were centrifuged at 8000 rpm/min and 4 °C for 10 min. The supernatants were then used for Interferon gamma (IFN-γ), Tumor necrosis factor α (TNF-α), Interleukin-2 (IL-2), aspartate aminotransferase (AST), alanine aminotransferase (ALT), alpha-fetoprotein (AFP), Fas, and FasL analyses by ELISA in accordance with the kit instructions (Shanghai Langton Biotechnology Co., Ltd., Shanghai, China), respectively.

***HepG2 cell culture and drug administration***

The mouse HCC H22 cell strain (Jiangsu Chi Scientific Co., Ltd, Jiangsu, China) was cultured in DMEM culture medium containing 1% streptomycin and 10% fetal bovine serum (Gibco, Thermo Fisher Scientific, Waltham, MA, United States) (100 μg/mL penicillin, 100 μg/mL streptomycin) in an incubator at 37 °C, 5% CO2 and 95% of relative saturation humidity. Cells at the density of 1 × 105/mL were inoculated into 6-well plates, and after culture for 24 h the medium was removed. 4.0 g MJF was added to 20 mL 50% methanol and treated with ultrasonic extraction for 20 min (700 W, 40 kHz), and the liquid was filtered and dried. 1.0 g MJF were mixed with 0.5 mL DMSO, diluted with DMEM culture medium to 10 mg/mL, 20 mg/mL, 30 mg/mL, and 40 mg/mL, and then added to a 6-well plate with 1 mL of MJF in each well (M1, M2, M3, and M4). The Transforming growth factor β1(TGF-β1) inhibitor Ly364947 (# HY-13462, MedChem Express Co., Ltd., NJ, United States) was adjusted to 1 μM and 2.5 μM, respectively, and added to 6-well plates with 1 mL of LY364947 in each well. M2 + LY-1 and M4 + LY-2 groups contained 20 mg/mL and 40 mg/mL of MJF each and 1 μM Ly364947. 1 mL culture medium was added to the Blank group. All groups were cultured for 8 h.

***Quantitative RT-qPCR analysis***

Tumor tissue was placed in TRlzol reagent to obtain a homogenate, and total RNA was extracted according to the manufacturer’s instructions. The reverse transcription kit (Trans Script One-Step gDNA Removal and cDNA Synthesis Super Mix, Beyotime Biotechnology Co., Ltd., Shanghai, China) was used to reverse transcribe the extracted RNA into cDNA and processed as previously described[18]. The total RNA in HepG2 cells in each group was processed in the same way. The primer sequences for RT-qPCR of tumor tissue and HepG2 cells are listed in Tables 2 and 3.

***Western blotting assay for target protein detection***

Tumor tissue proteins from the mice in each group were extracted with RIPA reagent. Proteins were separated by 10% SDS-PAGE and then transferred onto PVDF membranes (Beyotime Biotechnology Co., Ltd., Shanghai, China). The membranes were washed, blocked with BSA blocking solution for 2 h, and then incubated overnight with anti-β-actin (# 20536-1-AP), anti-TGF-β1 (# 21898-1-AP), anti- Mothers against decapentaplegic homolog(SMAD) 4 (# 10231-1-AP), anti-SMAD7 (# 25840-1-AP) (Proteintech Group, Inc., Rosemont, IL, United States), anti-SMAD2 (# 5339S), and anti-phosphorylated-SMAD2 (# 3108S, Cell Signaling Technology, Danvers, MA, United States) at 4 °C. After washing with TBST 3 times for 10 min each time, the membranes were incubated with secondary antibodies (Goat Anti-Rabbit IgG H + L) (# SA00001-2, Proteintech Group, Inc., Rosemont, IL, United States) for 2 h at room temperature. Immunoreactivity was determined using ECL glow (Beyotime Biotechnology Co., Ltd., Shanghai, China). Data analysis was conducted *via* Image J 1.8.0 software (National Institutes of Health, Bethesda, MD, United States). Protein in HepG2 cells from each group was processed using the same steps as above.

***Statistical analysis***

Statistical analyses were performed with SPSS 25.0 software (IBM Corporation, Armonk, NY, United States) using one-way ANOVA and data were expressed as the mean ± SD. *P* < 0.05 was considered statistically significant, and *P* < 0.01 was considered very significant. RT-qPCR data were analyzed by the 2-△△ Ct algorithm[19].

**RESULTS**

***MJF ingredient identification in plasma after oral administration***

A comprehensive MN based on LC-MS/MS spectra in order to reveal absorbable ingredients in MJF was performed as shown in Figure 2B. The MN map contained 933 precursor ions, including 137 clusters (nodes ＞ 2) and 352 single nodes. A total of 17 main prototype components (P1-17) were screened out by the GNPS MS database, based on the mass measurements and fragmentation patterns confirmed by reference substances. These compounds were identified as cysteine, gallic acid, matrine, sophocarpine, protocatechuic acid, caffeate, hyperoside, quercetin, isoquercitrin, rutin, kaempferol-3-o-rutinoside, astragalin, naringenin, kaempferol, ellagic acid, ferulic acid, and isorhamnetin (Figure 2, Table 4). These compounds were of three main types: polyphenol acids, flavonoids, and alkaloids, all of which were selected and used for the following target prediction in network pharmacology analysis.

***Network pharmacology construction of the anti-HCC targets of MFJ and pathway enrichment analysis***

Seventeen ingredients related 1232 genes to HCC related genes were mapped, a total of 166 targets were obtained and an ingredients-anti-HCC-target network was established. The degree of each node was measured by the Network Analyzer App in Cytoscape (Figure 3A). The degree of one node indicates the number of nodes that have direct interactions with it, the higher degree one node has, the more biological processes it participates in, and the more biological importance it possesses.

From the topological analysis of 177 ingredients-anti-HCC-targets through the PPI network generated by the STRING database, 72 predicted targets were acquired. By uploading all these predicted targets into the Metascape database, we obtained the GO and KEGG pathways to enrich the analysis. Figure 3B lists the top 5 GO pathways to enrich the analysis indicating that MJF could respond to inorganic substances and xenobiotic stimulus *etc*. of Biological Processes (BP), kinase binding and transcription factor binding *etc*. of Cellular Components (CC), and membrane raft, vesicle lumen *etc*. of Molecular Functions (MF). Among the top 15 KEGG pathways which enriched the analysis (Figure 3B), only 6 of them were related to HCC including pathways in cancer, hepatitis B, proteoglycans in cancer, hepatitis C, HCC, and the TGF-β signaling pathway. From the heatmap in Figure 3B, 14 genes with the most significantly different abundance related to the 6 KEGG pathways of HCC were clustered, including FAS, *BCL2*, TNF, IL2, *BAX*, IFNG, TGFB1, SMAD4, MMP9 SRC, EGF, STAT1, IGF2, and IGF1R. A comprehensive predicted ingredient-anti-HCC-pathway-target network is shown in Figure 3C, where 17 potentially effective compounds related to the 6 pathways of HCC, from which, we clustered 8 hub-targets had a greater degree (above the median of 34.763) from the topological analysis of the network including TNF, *BAX*, *BCL2*, TGFB1, IFNG, FAS, IL2 and SMAD4 (Figure 3D).

***Regulatory effects of MJF on H22 tumor-bearing mice***

As displayed in Figure 4A, except for the Model group, the average body weight in the other groups all showed varying rapid gain. Compared with the Blank group, H22 tumor-bearing mice in the Model group had a much higher spleen index and lower thymus index (*P* < 0.05), due to H22 bearing tumors causing splenomegaly and thymic atrophy in mice. The CTX and MJF groups (M-L, M-M and M-H) revealed a significantly reduced spleen index and increased thymus index relative to the Model group, and in the MJF groups these levels progressed with increased dose (*P* < 0.05, *P* < 0.01). Figure 4B indicates that the concentration of AFP (HCC indicator), ALT and AST (liver function indicators), and TNF-α, IFN-γ, and IL-2 (immune factors) in the Model group markedly increased compared with the Blank group (*P* < 0.05), which confirmed that H22 tumors may affect immune action and inflammation in the liver and reduce liver function in mice. Compared with the Model group, CTX and MJF effectively reduced the concentration of AFP, ALT, AST, TNF-α and IFN-γ, and increased the concentration of IL2. With an increase in dose, the MJF mid and high dose groups (M-M and M-H) showed significant enhancement in adjusting the concentration of the above indicators (*P* < 0.05, *P* < 0.01).

As shown in Figure 4C, the size of the tumor in the Model group was larger and the color was darker, blood and vessels were clearly observed on the surface, while the tumors in the other groups were pale, and the size of the tumor and the average inhibitory rate in the 3 MJF groups (M-L, M-M and M-H) gradually changed with increased dose, respectively. Figure 4D shows the microscopic images and local enlarged images of HE stained sections of tumor tissue from each group. The tumor cells in the Model group were densely arranged with high cell density and large nuclei, and necrotic cells and cytoplasm were rarely seen. In the CTX group, tumor cells were loosely arranged, necrotic cells showed nucleus necrosis and rupture, and the cytoplasm was condensed and shrunken. In contrast, the three MJF groups all had different degrees of necrosis and apoptotic cell areas. The cytoplasm was highly agglutinated and condensed. In the MJF high dose group (M-H), the number of dead cells and round apoptotic bodies were more numerous, the size of the cells varied, and the connective tissue was more obvious than in the other two MJF groups (M-L and M-M).

We evaluated the concentration of the cell apoptotic factors Fas and FasL, and the mRNA expression of *Bax* and *Bcl2*, two cytokines that can form homologous or heterologous dimers to regulate apoptosis, in order to determine the effect of MJF in improving the apoptosis of cancer cells. As shown in Figure 5A, the concentrations of Fas and FasL in the Model group were markedly increased relative to the Blank group, whereas, CTX and MJF (M-L, M-M and M-H) reduced the concentrations, respectively (*P* < 0.01). In addition, CTX and MJF also up-regulated the relative mRNA expression of *Bax* and down-regulated that of *Bcl2* compared to the Model group (*P* < 0.01) (Figure 5B). Moreover, Western blot analysis was performed to determine the protein level of TGF-β1 and SMAD4, and it was demonstrated that CTX and MJF significantly increased the expression of TGF-β1 and SMAD4, and the expression levels in the MJF mid and high dose groups were even higher than that in the CTX group (*P* < 0.01) (Figure 5C).

***MJF modulated the TGF-β1/SMAD pathway, immune and apoptotic cytokines in HepG2 cells***

Western blot analysis was used to determine the protein expression of TGF-β1, SMAD2, p-SMAD2, SMAD4, and SMAD7, and we evaluated the effectiveness of MJF in regulating immune escape factors and promoting apoptosis in HepG2 cells, as the TGF-β1/SMAD signaling pathway plays an essential role in the development and invasion of HCC. The results showed that MJF (10 mg/mL to 40 mg/mL effectively increased the expression of TGF-β1, SMAD2, p-SMAD2 and SMAD4, and reduced the expression of SMAD7 protein relative to the levels in the Control group (MJF 0 mg/mL), respectively (*P* < 0.05) (Figure 6A). Furthermore, the results also showed that, compared with the Control group (MJF 0 mg/mL), mRNA expression of the immune cytokines, TNF-α and IFN-γ, in MJF (10 mg/mL to 40 mg/mL) was markedly decreased, and mRNA expression of the apoptosis cytokine, *Bax* in MJF (10 mg/mL to 40 mg/mL) was significantly increased and that of *Bcl2* was reduced (*P* < 0.05) (Figure 6B and C).

***MJF alleviated the modulation of TGF-β1 inhibitor (LY364947) on the TGF-β1/SMAD pathway, and immune and apoptotic cytokines in HepG2 cells***

To evaluate the regulation of MJF on the TGF-β1/SMAD signaling pathway and both immune and apoptotic cytokines in HepG2 cells, LY364947, a TGF-β1 inhibitor, was added to the cell culture. As demonstrated in Figure 7A, relative to the Control group (LY364947 0 μM and MJF 0 mg/mL), LY364947 effectively inhibited the expression of TGF-β1, SMAD2, p-SMAD2 and SMAD4 protein and promoted that of SMAD7 (LY364947 2.5 μM and MJF 0 mg/mL), while, MJF (LY364947 2.5 μM, MJF 20 and 40 mg/mL) reduced the effect of LY364947 by improving the expression of TGF-β1, SMAD2, p-SMAD2 and SMAD4, and down regulating SMAD7 (*P* < 0.05).

With regard to the immune cytokines, TNF-α and IFN-γ, compared to the Control group (LY364947 0 μM and MJF 0 mg/mL), LY364947 significantly increased mRNA expression of TNF-α and IFN-γ (LY364947 2.5 μM and MJF 0 mg/mL), and MJF (LY364947 2.5 μM, MJF 20 and 40 mg/mL) showed a marked decrease in these two cytokines (*P* < 0.05) (Figure 7B). Moreover, compared with the Control group LY364947 0 μM and MJF 0 mg/mL), the expression of *Bax* mRNA was inhibited and that of *Bcl2* was improved after treatment with LY364947 (LY364947 2.5 μM and MJF 0 mg/mL), yet, MJF (LY364947 2.5 μM, MJF 20 and 40 mg/mL) weakened this effect by increasing *Bax* and reducing *Bcl2*, respectively (*P* < 0.05) (Figure 7C).

**DISCUSSION**

HCC is a malignant tumor with high morbidity and mortality worldwide[20]. At present, the main clinical treatments for malignant liver tumors are surgery, radiation, and chemotherapy[21]. Common chemotherapy drugs have side effects such as cytotoxicity, multiple drug resistance, *etc*., and have different degrees of impact on liver function and the immune system[22]. TCM has a particular function in cancer treatment and prevention due to its high multi-target biological activity and low toxicity[23]. The long history and extensive study of TCM indicate its potential advantages in alleviating symptoms and improving quality of life in different patterns and stages of the disease[24]. As a Chinese patent medicine, MJF has been used in the treatment of liver cancer since the 1980s, with the exception of HCC, and has also been proved to have anti-inflammatory effects, enhances immunity, and improves liver function. Thus, in the present study, we mainly focused on exploring the mechanism of action of MJF.

In a recent study, the MN technique associated with HPLC-ESI-TOF-MS was employed in studies of natural products derived from plants, microorganisms, marine organisms, and other biological sources[25]. As a visual computational strategy, MN can be intuitively implemented based on a comparison of the theoretical MS/MS spectra to test MS/MS spectra and establish the relative network by clustering similar structures with similar mass spectra for compound identification[26]. In this study, we imported this recent approach, and established the MN of MJF solution and plasma after oral administration, and by merging the two MNs, the shared compounds were thought to be the absorbable constituents of MJF. To verify this, we also used reference substances to identify the 17 ingredients obtained from MN.

We then introduced network pharmacology to establish an image of the function and behavior of the biological network of MJF, identify potential targets and pathways of the drugs related to the disease using topology and computational methods, and explored the topology parameters of the 17 ingredients and their related targets in anti-HCC among all the ingredients-anti-HCC-pathways-targets. As a consequence, targets including TGFB1, SMAD4, TNF, IFNA1, IL2, *BAX*, *BCL2*, and FAS (TNF superfamily receptor 6) were screened out.

The TGF-β1/SMAD signaling pathway plays an important role in the development and invasion of HCC[27,28]. Cytoplasmic protein SMAD is the most critical and important signal transduction factor in the TGF β signaling pathway. When the TGF-β pathway is activated, phosphorylated SMAD2 combines with SMAD4 to form a complex, and then enters the nucleus to activate the expression of downstream target genes. SMAD 7 is a TGF-β signaling inhibitory factor, which is localized in the cell nucleus, and can regulate the activity of TGF-β[29]. IL-2 is an important cytokine which regulates immune function, promotes the proliferation and activation of T cells, and stimulates the proliferation of natural killer cells[30,31]. TNF-α and IFN-γ are essential cellular immune molecules, which affect the immune escape of cells. Clinical studies have shown that disordered TNF-α and IFN-γ levels have a significant impact on the stability of the body’s internal environment, leading to abnormal immune function in patients, and inducing the occurrence and progression of tumors[32]. Tumor cells can avoid apoptosis by up-regulating *Bcl2* and down-regulating *Bax*[33]. *Bax* and *Bcl2* antagonize each other in apoptosis regulation of HCC cells. With the decrease or deletion of *Bax* expression, apoptosis of HCC cells is gradually weakened, which may be an important reason for the rapid growth and enlargement of tumors. Fas is a cell surface death receptor and an apoptosis signaling molecule. Fas which binds to FasL activates and transmits apoptosis signals, which is an important pathway in inducing tumor cell apoptosis. Previous research showed that the apoptosis of cancer cells mediated by Fas and FasL is an important part of the body’s immune surveillance[34], and the abnormal expression of Fas and FasL can lead to disordered apoptosis, which results in massive cell proliferation due to escaping the killing effect of cytotoxic T cells[35,36].

In this study, we evaluated the impact of MJF on HCC using both *in vivo* (H22 tumor-bearing mice) and *in vitro* (HepG2 cells) models (Figure 8). The results indicated that MJF could prevent HCC by improving body weight gain and tumor inhibition rate, protecting immune organs and liver function, affecting immunity and apoptosis, and up-regulating the TGF-β1/SMAD signaling pathway, by increasing the relative expression of TGF-β1, SMAD3, p-SMAD2 and SMAD4 and decreasing SMAD7, reducing immune factors TNF-α and IFN-γ, and decreasing the apoptosis cytokines Fas, FasL and *Bcl2*/*Bax*. In addition, to verify these findings, we treated HepG2 cells with the TGF-β1 inhibitor LY364947, which inhibited the TGF-β1/SMAD signaling pathway, increased Laminin Subunit Alpha 4 (LAMA4), TNF-α, IFN-γ, Fas, FasL, and *Bcl2*/*Bax* expression. However, MJF significantly inhibited the effect of LY364947. This suggested that MJF has potential effects on HCC by regulating the TGF-β1/SMAD pathway, immune and apoptotic cytokines.

Based on the identification of absorbable ingredients in mouse serum, we mainly focused on the fundamental study of potential anti-HCC targets of MJF, and intensive research on the mechanism of tumor cell apoptosis and immunology are still required. Moreover, other absorbable ingredients also need to be identified.

**CONCLUSION**

Our results demonstrated that MJF inhibits HCC by activating the TGF-β1/SMAD signaling pathway, immune and apoptotic cytokines, which may be due to the mechanisms of MJF in adjusting immune escape and apoptosis.

**ARTICLE HIGHLIGHTS**

***Research background***

Hepatocellular carcinoma (HCC) is one of the most common digestive system cancers with high mortality rates worldwide.

***Research motivation***

Considerable effort has been expended in understanding the mechanism of Mu Ji Fang Granules (MJF) on tumor immunology in the treatment of HCC.

***Research objectives***

Our study explored the mechanism of MJF adjusting immune escape and apoptosis.

***Research methods***

We conducted Molecule Network related to High Performance Liquid Chromatography-Electron Spray Ionization-Time of Flight- Mass Spectrometry to identify the absorbable ingredients of MJF, and hub potential anti-HCC targets were screened using network pharmacology and pathway enrichment analysis. Both *in vivo* and *in vitro* experiments were demonstrated, and multiply processes including Histopathological analysis, Immunosorbent Assay, RT-qPCR, Western blotting assays were to adopted to explore the function MJF inhibits HCC.

***Research results***

We found that MJF improved body weight gain and tumor inhibition rate in H22 tumor-bearing mice, protected immune organs and liver function, reduced the HCC indicator alpha-fetoprotein, affected immunity and apoptosis, and up-regulated the Transforming growth factor β1(TGF-β1)/SMAD signaling pathway, by increasing the relative expression of TGF-β1, SMAD2, p-SMAD2 and SMAD4 and decreasing SMAD7, reducing immune factors Tumor necrosis factor α and Interferon gamma, decreasing apoptosis cytokines Fas, FasL and *Bcl2*/*Bax*, and inhibiting the effect of LY364947 in HepG2 cells.

***Research conclusions***

Our findings suggested that MJF inhibits HCC by activating the TGF-β1/SMAD signaling pathway, and affecting immune and apoptotic cytokines.

***Research perspectives***

Considerable effort has been expended in understanding the anti-HCC mechanism of MJF, all of which due to MJF’s particular participate in adjusting immune escape and apoptosis.

**REFERENCES**

1 **International Agency for Research on Cancer.** World Cancer Report: Cancer Research for Cancer Prevention.Wild CP, Weiderpass E, Stewart BW, Editor. Switzerland: WHO Press, World Health Organization, 2020: 355-367

2 **Zheng RS**, Sun KX, Zhang SW, Zeng HM, Zou XN, Chen R, Gu XY, Wei WW, He J. [Report of cancer epidemiology in China, 2015]. *Zhonghua Zhong Liu Za Zhi* 2019; **41**: 19-28 [PMID: 30678413 DOI: 10.3760/cma.j.issn.0253-3766.2019.01.005]

3 **Cai L**, Zou S, Liang D, Luan L. Structural characterization, antioxidant and hepatoprotective activities of polysaccharides from Sophorae tonkinensis Radix. *Carbohydr Polym* 2018; **184**: 354-365 [PMID: 29352929 DOI: 10.1016/j.carbpol.2017.12.083]

4 **Zhang Y**, Xiong H, Xu X, Xue X, Liu M, Xu S, Liu H, Gao Y, Zhang H, Li X. Compounds Identification in Semen Cuscutae by Ultra-High-Performance Liquid Chromatography (UPLCs) Coupled to Electrospray Ionization Mass Spectrometry. *Molecules* 2018; **23** [PMID: 29772791 DOI: 10.3390/molecules23051199]

5 **Zhou YY**, Song HJ, Guo S, Wang Y, Gao HR, Zhang XJ, Sun YP, Liu Y, Yang BY, Kuang HX. A new triterpene from the green walnut husks of Juglans mandshurica Maxim. *J Nat Med* 2019; **73**: 800-804 [PMID: 31177356 DOI: 10.1007/s11418-019-01309-4]

6 **Kaplan Ö,** Gökşen Tosun N, Özgür A, Erden Tayhan S, Bilgin S, Türkekul İ, Gökce İ. Microwave-assisted green synthesis of silver nanoparticles using crude extracts of Boletus edulis and Coriolus versicolor: Characterization, anticancer, antimicrobial and wound healing activities. *Journal of Drug Delivery Science and Technology*. 2021;64 [DOI:10.1016/j.jddst.2021.102641]

7 **Li F**, Li Y, Deng ZP, Zhu XJ, Zhang ZG, Zhang XD, Tian JL, Li W, Zhao P. Traditional uses, phytochemistry, pharmacology and clinical applications of Cortex Juglandis Mandshuricae: A comprehensive review. *J Ethnopharmacol* 2022; **285**: 114887 [PMID: 34864127 DOI: 10.1016/j.jep.2021.114887]

8 **Wang L,** Song YR. [Observation of Therapeutic Effects of Compound Mujj Granules in the Treatment of Chronic Hepatitis B with Hepatic Fibrosis]. *Liaoning Zhongyi Zazhi* 2009; **36**:408-409

9 **Duan J,** Jiang H, Ding Z, Xiao H, Xia W, Zhou YQ. [Clinical effect of compound muji granules in treating patients with compensatory cirrhosis induced by hepatitis B]. *Zhongguo Yixue Gongcheng* 2017; **(12)**:8-12 [DOI: 10.19338/j.issn.1672-2019.2017.12.002]

10 **Sun J,** Guo LY, Xue-Jun GU. [Effects of Muji granules on lymphocyte functions in tumor-bearing mice]. *Shiyong Yixue Zazhi* 2010; **26**:2120-2122 [DOI: 10.3969/j.issn.1006-5725.2010.12.023]

11 **Wang H**, Hou Y, Ma X, Cui L, Bao Y, Xie Y, Li S, Meng X, Li J, Bai G. Multi-omics analysis reveals the mechanisms of action and therapeutic regimens of traditional Chinese medicine, Bufei Jianpi granules: Implication for COPD drug discovery. *Phytomedicine* 2022; **98**: 153963 [PMID: 35121390 DOI: 10.1016/j.phymed.2022.153963]

12 **Piñero J**, Ramírez-Anguita JM, Saüch-Pitarch J, Ronzano F, Centeno E, Sanz F, Furlong LI. The DisGeNET knowledge platform for disease genomics: 2019 update. *Nucleic Acids Res* 2020; **48**: D845-D855 [PMID: 31680165 DOI: 10.1093/nar/gkz1021]

13 **Lee L**, Wang K, Li G, Xie Z, Wang Y, Xu J, Sun S, Pocalyko D, Bhak J, Kim C, Lee KH, Jang YJ, Yeom YI, Yoo HS, Hwang S. Liverome: a curated database of liver cancer-related gene signatures with self-contained context information. *BMC Genomics* 2011; **12** Suppl 3: S3 [PMID: 22369201 DOI: 10.1186/1471-2164-12-S3-S3]

14 **Su WH**, Chao CC, Yeh SH, Chen DS, Chen PJ, Jou YS. OncoDB.HCC: an integrated oncogenomic database of hepatocellular carcinoma revealed aberrant cancer target genes and loci. *Nucleic Acids Res* 2007; **35**: D727-D731 [PMID: 17098932 DOI: 10.1093/nar/gkl845]

15 **Daina A**, Michielin O, Zoete V. SwissTargetPrediction: updated data and new features for efficient prediction of protein targets of small molecules. *Nucleic Acids Res* 2019; **47**: W357-W364 [PMID: 31106366 DOI: 10.1093/nar/gkz382]

16 **Szklarczyk D**, Gable AL, Nastou KC, Lyon D, Kirsch R, Pyysalo S, Doncheva NT, Legeay M, Fang T, Bork P, Jensen LJ, von Mering C. The STRING database in 2021: customizable protein-protein networks, and functional characterization of user-uploaded gene/measurement sets. *Nucleic Acids Res* 2021; **49**: D605-D612 [PMID: 33237311 DOI: 10.1093/nar/gkaa1074]

17 **Zhou Y**, Zhou B, Pache L, Chang M, Khodabakhshi AH, Tanaseichuk O, Benner C, Chanda SK. Metascape provides a biologist-oriented resource for the analysis of systems-level datasets. *Nat Commun* 2019; **10**: 1523 [PMID: 30944313 DOI: 10.1038/s41467-019-09234-6]

18 **Liu Z**, Luo H, Zhang L, Huang Y, Liu B, Ma K, Feng J, Xie J, Zheng J, Hu J, Zhan S, Zhu Y, Xu Q, Kong W, Wang X. Hyperhomocysteinemia exaggerates adventitial inflammation and angiotensin II-induced abdominal aortic aneurysm in mice. *Circ Res* 2012; **111**: 1261-1273 [PMID: 22912384 DOI: 10.1161/CIRCRESAHA.112.270520]

19 **Livak KJ**, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. *Methods* 2001; **25**: 402-408 [PMID: 11846609 DOI: 10.1006/meth.2001.1262]

20 **Liu Z**, Suo C, Mao X, Jiang Y, Jin L, Zhang T, Chen X. Global incidence trends in primary liver cancer by age at diagnosis, sex, region, and etiology, 1990-2017. *Cancer* 2020; **126**: 2267-2278 [PMID: 32201944 DOI: 10.1002/cncr.32789]

21 **Korean Liver Cancer Association (KLCA)**; National Cancer Center (NCC), Goyang, Korea. 2018 Korean Liver Cancer Association-National Cancer Center Korea Practice Guidelines for the Management of Hepatocellular Carcinoma. *Korean J Radiol* 2019; **20**: 1042-1113 [PMID: 31270974 DOI: 10.3348/kjr.2019.0140]

22 **Marin JJG**, Herraez E, Lozano E, Macias RIR, Briz O. Models for Understanding Resistance to Chemotherapy in Liver Cancer. *Cancers (Basel)* 2019; **11** [PMID: 31671735 DOI: 10.3390/cancers11111677]

23 **Khazir J**, Riley DL, Pilcher LA, De-Maayer P, Mir BA. Anticancer agents from diverse natural sources. *Nat Prod Commun* 2014; **9**: 1655-1669 [PMID: 25532303]

24 **Hsiao WL**, Liu L. The role of traditional Chinese herbal medicines in cancer therapy—from TCM theory to mechanistic insights. *Planta Med* 2010; **76**: 1118-1131 [PMID: 20635308 DOI: 10.1055/s-0030-1250186]

25 **Fox Ramos AE**, Evanno L, Poupon E, Champy P, Beniddir MA. Natural products targeting strategies involving molecular networking: different manners, one goal. *Nat Prod Rep* 2019; **36**: 960-980 [PMID: 31140509 DOI: 10.1039/c9np00006b]

26 **Wang Z**, Kim U, Liu J, Cheng C, Wu W, Guo S, Feng Y, Quinn RJ, Hou Y, Bai G. Comprehensive TCM molecular networking based on MS/MS in silico spectra with integration of virtual screening and affinity MS screening for discovering functional ligands from natural herbs. *Anal Bioanal Chem* 2019; **411**: 5785-5797 [PMID: 31236650 DOI: 10.1007/s00216-019-01962-4]

27 **Wakefield LM**, Roberts AB. TGF-beta signaling: positive and negative effects on tumorigenesis. *Curr Opin Genet Dev* 2002; **12**: 22-29 [PMID: 11790550 DOI: 10.1016/s0959-437x(01)00259-3]

28 **Boye A**, Kan H, Wu C, Jiang Y, Yang X, He S, Yang Y. MAPK inhibitors differently modulate TGF-β/Smad signaling in HepG2 cells. *Tumour Biol* 2015; **36**: 3643-3651 [PMID: 25560488 DOI: 10.1007/s13277-014-3002-x]

29 **Syed V**. TGF-β Signaling in Cancer. *J Cell Biochem* 2016; **117**: 1279-1287 [PMID: 26774024 DOI: 10.1002/jcb.25496]

30 **Waldmann TA**. The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design. *Nat Rev Immunol* 2006; **6**: 595-601 [PMID: 16868550 DOI: 10.1038/nri1901]

31 **Engel AL**, Holt GE, Lu H. The pharmacokinetics of Toll-like receptor agonists and the impact on the immune system. *Expert Rev Clin Pharmacol* 2011; **4**: 275-289 [PMID: 21643519 DOI: 10.1586/ecp.11.5]

32 **Cui HX**, Tang L, Cheng FR, Yuan K. Antitumor Effects of Ethanol Extracts from Hyptis Rhomboidea in H(22) Tumor-bearing Mice. *Pharmacogn Mag* 2017; **13**: 571-575 [PMID: 29200715 DOI: 10.4103/pm.pm\_314\_16]

33 **Croker BA**, O’Donnell JA, Nowell CJ, Metcalf D, Dewson G, Campbell KJ, Rogers KL, Hu Y, Smyth GK, Zhang JG, White M, Lackovic K, Cengia LH, O’Reilly LA, Bouillet P, Cory S, Strasser A, Roberts AW. Fas-mediated neutrophil apoptosis is accelerated by Bid, Bak, and Bax and inhibited by Bcl-2 and Mcl-1. *Proc Natl Acad Sci U S A* 2011; **108**: 13135-13140 [PMID: 21768356 DOI: 10.1073/pnas.1110358108]

34 **Lee SH**, Shin MS, Lee HS, Bae JH, Lee HK, Kim HS, Kim SY, Jang JJ, Joo M, Kang YK, Park WS, Park JY, Oh RR, Han SY, Lee JH, Kim SH, Lee JY, Yoo NJ. Expression of Fas and Fas-related molecules in human hepatocellular carcinoma. *Hum Pathol* 2001; **32**: 250-256 [PMID: 11274632 DOI: 10.1053/hupa.2001.22769]

35 **Fukuzawa Y**, Takahashi K, Furuta K, Tagaya T, Ishikawa T, Wada K, Omoto Y, Koji T, Kakumu S. Expression of fas/fas ligand (fasL) and its involvement in infiltrating lymphocytes in hepatocellular carcinoma (HCC). *J Gastroenterol* 2001; **36**: 681-688 [PMID: 11686478 DOI: 10.1007/s005350170031]

36 **Alderson MR**, Tough TW, Davis-Smith T, Braddy S, Falk B, Schooley KA, Goodwin RG, Smith CA, Ramsdell F, Lynch DH. Fas ligand mediates activation-induced cell death in human T lymphocytes. *J Exp Med* 1995; **181**: 71-77 [PMID: 7528780 DOI: 10.1084/jem.181.1.71]

**Footnotes**

**Institutional animal care and use committee statement:** All experimental procedures were performed with the approval of the animal guidelines and protocols established by the Medicine Ethics Review Committee of Animal Experiments of Liaoning University of Traditional Chinese Medicine. The study was reviewed and approved by the Animal Ethics Committee of The Affiliated Hospital of Liaoning University of TCM. [Approval No. 2019YS(DW)-033-01]

**Conflict-of-interest statement:** All the authors report no relevant conflicts of interest for this article.

**Data sharing statement:** Data are available from the corresponding authors upon request (Email: mxsvvv@163.com).

**ARRIVE guidelines statement:** The authors have read the ARRIVE Guidelines, and the manuscript was prepared and revised according to the ARRIVE Guidelines.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Unsolicited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review started:** December 20, 2022

**First decision:** January 9, 2023

**Article in press:**

**Specialty type:** Oncology

**Country/Territory of origin:** China

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B

Grade C (Good): C

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Andersen JB, Denmark; Nardone G, Italy **S-Editor:** Li L **L-Editor:** A **P-Editor:**

**Figure Legends**

图示

描述已自动生成

**Figure 1 Establishment of H22 tumor-bearing mice.** CTX: Cyclophosphamide; MJF: Mu Ji Fang Granules.

图示

描述已自动生成

图片包含 图形用户界面

描述已自动生成

**Figure 2 Identification of the absorbable ingredients in Mu Ji Fang Granules using molecular networking.** A: Workflow of the molecular networking approach; B: Whole molecule networking profile of Mu Ji Fang Granules after oral administration; C: Absorbable ingredients identified using reference substances. mzXML: A kind of format for Mass spectrometry data file. GNPS: Website of Global Nature Products Social Molecular Networking; LC-MS/MS: Liquid Chromatograph Mass Spectrometer.

图表

描述已自动生成

****

**Figure 3 Network pharmacology construction and pathway enrichment analysis of Mu Ji Fang Granules.** A: Ingredients-anti-hepatocellular carcinoma (HCC)-targets network of Mu Ji Fang Granules (MJF) (diamond represents ingredients and ellipse represents targets). The color of the nodes from blue to red indicate the degree from low the high; B: Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis and heatmap of the 14 most significantly different abundant genes related to the 6 KEGG pathways of HCC (BP: Represents Biological Process; CC: Represents Cellular Component; and MP: Represents Molecular Function); C: Ingredient-anti-HCC-pathway-target network of MJF (diamond represents ingredients, octagon represents targets and V represents pathway). The color of the nodes from red to yellow to green to blue indicates the degree from high to low; D: Hub targets of MJF most closely related to HCC. TNF: Tumor necrosis factor; TGF: Transforming growth factor; SMAD4: Mothers against decapentaplegic homolog 4; IL: Interleukin; FAS: TNF superfamily receptor 6.

图表, 条形图

描述已自动生成 图表, 条形图

描述已自动生成 图片包含 日历

描述已自动生成

****

**Figure 4 Mu Ji Fang Granules improved average body weight, spleen and thymus indices, decreased the concentration of hepatocellular carcinoma indicators, liver function indicators and immune factors.** A: Average body weight, spleen index and thymus index (*n* = 8); B: Concentrations of hepatocellular carcinoma indicator alpha-fetoprotein, liver function indicators alanine aminotransferase and aspartate aminotransferase and immune factors Tumor necrosis factor α, Interferon gamma and Interleukin-2 in serum (*n* = 8); C: Tumor tissue from H22 tumor-bearing mice and the tumor inhibitory rate (*n* = 8); D: hematoxylin and eosin staining of tumor tissue pathology sections from H22 tumor-bearing mice (*n* = 3). Data are shown as the mean ± standard deviation. a*P* < 0.01 *vs* Blank. b*P* < 0.01 *vs* Model. c*P* < 0.05 *vs* Model. d*P* < 0.01 *vs* M-L. e*P* < 0.05 *vs* M-L.

图表, 条形图

描述已自动生成 图表, 条形图

描述已自动生成

**Figure 5 Mu Ji Fang Granules improved apoptosis and regulated the Transforming growth factor β1/ Mothers against decapentaplegic homolog signaling pathway in H22 tumor-bearing mice.** A: The concentration of Fas and FasL in serum (*n* = 8); B: Relative expression of *Bax* and *Bcl2* mRNA in tumor tissue (*n* = 3); C: Relative expression of Transforming growth factor β1 and Mothers against decapentaplegic homolog 4 protein in tumor tissue (*n* = 3). Data are shown as the mean ± standard deviation. a*P* < 0.01 *vs* Blank. *bP* < 0.01 *vs* Model. *dP* < 0.01 *vs* M-L.

图表, 条形图

描述已自动生成 图表, 条形图, 箱线图

描述已自动生成

****

**Figure 6 Mu Ji Fang Granules modulated the Transforming growth factor β1/ Mothers against decapentaplegic homolog signaling pathway and improved the expression of immune and apoptotic cytokines in HepG2 cells.** A: Relative expression of Transforming growth factor β1, Mothers against decapentaplegic homolog (SMAD) 2, p-SMAD2, SMAD4, and SMAD7 protein; B: Relative expression of Tumor necrosis factor α and Interferon gamma mRNA; C: Relative expression of *Bax*, and *Bcl2* mRNA (*n* = 4). Data are shown as the mean ± standard deviation. a*P* < 0.01 *vs* Control [Mu Ji Fang Granules (MJF) 0 mg/mL]. b*P* < 0.01 *vs* MJF 10 mg/mL.

图表, 条形图

描述已自动生成

图表, 条形图, 箱线图

描述已自动生成

**Figure 7 Mu Ji Fang Granules alleviated the modulation of Transforming growth factor β1 inhibitor (LY364947) on the Transforming growth factor β1/** **Mothers against decapentaplegic homolog signaling pathway, immune and apoptotic cytokines in HepG2 cells.** A: Relative expression of Transforming growth factor β1(TGF-β1), Mothers against decapentaplegic homolog (SMAD) 2, p-SMAD2, SMAD4, and SMAD7 protein following treatment of HepG2 cells with TGF-β1 inhibitor (LY364947); B: Relative expression of Tumor necrosis factor α and Interferon gamma mRNA following treatment of HepG2 cells with TGF-β1 inhibitor (LY364947); C: Relative expression of *Bax*, and *Bcl2* mRNA following treatment of HepG2 cells with TGF-β1 inhibitor (LY364947) (*n* = 4). Data are shown as mean ± standard deviation. a*P* < 0.01 *vs* Control [Mu Ji Fang Granules (MJF) 0 mg/mL]. b*P* < 0.05 *vs* Control [Mu Ji Fang Granules (MJF) 0 mg/mL]. c*P* < 0.01 *vs* Mu Ji Fang Granules 10 mg/mL. d*P* < 0.05 *vs* Mu Ji Fang Granules 10 mg/mL.

图示

描述已自动生成

**Figure 8 Overview of the possible anti-hepatocellular carcinoma effects of Mu Ji Fang Granules.** CTX: Cyclophosphamide; IFN-γ: Interferon gamma; TNF-α: Tumor necrosis factor α; IL: Interleukin; SMAD: Mothers against decapentaplegic homolog; TGF: Transforming grow; MJF: Mu Ji Fang Granules; AST: Aspartate aminotransferase; ALT: Alanine aminotransferase; AFP: Alpha-fetoprotein; HCC: Hepatocellular carcinoma.

**Table 1 Four herbs in Mu Ji Fang granules**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Herb** | **Latin name** | **Family and Genus** | **Plant** | **Medicinal parts** |
| Sophorae tonkinensis Radix | Sophorae tonkinensis Radix et rhizoma | Leguminosae | Sophora tonkinensis Gapnep | Root |
| Cuscutae Semen | Cuscutae semen | Convolvulaceae | Cuscuta australis R. Br. or  Cuscuta chinensis Lam | Seed |
| Juglans mandshurica Maxim | Juglans mandshurica Maxim | Juglandaceae | Juglans mandshurica | Bark |
| Coriolus versicolor | Coriolus versicolor | Basidiomycetes | Coriolus versicolor (L. ex Fr.) Quel | Fruit body |

**Table 2 Primer sequences for Real Time Quantitative PCR of tumor tissue**

|  |  |
| --- | --- |
| **Name of primers** | **Sequences** |
| *Bax-F* | *5’-AGGATGCGTCCACCAAGAA-3’* |
| *Bax-R* | *5’-CAAAGTAGAAGAGGGCAACCAC-3’* |
| *Bcl-2-F* | *5’-CAACACTCCCTCTTGACCTATGC-3’* |
| *Bcl-2-R* | *5’-GAAAATGTTCCCAAGTGAGTTAGA-3’* |
| *β-actin-F* | *5’-GTCCCTCACCCTCCCAAAAG-3’* |
| *β-actin-R* | *5’-GCTGCCTCAACACCTCAACCC-3’* |

**Table 3 Primer sequences for Real Time Quantitative PCR of HepG2 cells**

|  |  |
| --- | --- |
| **Name of primers** | **Sequences** |
| *TNF-α-F* | *5’-ATCGGTCCCAACAAGGAGGAGAAGT-3’* |
| *TNF-α-R* | *5’-ACGTGGGCTACGGGCTTGTCACTC-3’* |
| *IFN-γ-F* | *5’-ACAACCAGGCCATCAGCAACAACATA-3’* |
| *IFN-γ-R* | *5’-CTGTGGGTTGTTCAGCTCGAACTT-3’* |
| *Bax-F* | *5’-AAACTGGTGCTCAAGGCCC-3’* |
| *Bax-R* | *5’-AAAGTAGGAGAGGAGGCCGTC-3’* |
| *Bcl-2-F* | *5’-CAGGATAACGGAGGCTGGGATG-3’* |
| *Bcl-2-R* | *5’-TTCACTTGTGGCCCAGATAGG-3’* |
| *β-actin-F* | *5’-GGACCTGACTGACTACCTC-3’* |
| *β-actin-R* | *5’-TACTCCTGCTTGCTGAT-3’* |

TNF-α: Tumor necrosis factor α; INF-γ: Interferon gamma.

**Table 4 Compound identification in Mu Ji Fang Granules by High Performance Liquid Chromatography-Electron Spray Ionization-Time of Flight- Mass Spectrometry with reference substances**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **No.** | **RT (min)** | **[M-H/M+FA]-** | **Actual-M** | **Formula** | **Proposed compound** |
| 1 | 3.412 | 189.121 | 189.129 | C11H14N2O | Cytisine |
| 2 | 3.585 | 169.0149 | 169.0145 | C7H6O5 | Gallic acid |
| 3 | 3.607 | 249.2185 | 249.2179 | C15H24N2O | Matrine |
| 4 | 3.615 | 247.2023 | 247.2 | C15H22N2O | Sophocarpine |
| 5 | 4.997 | 153.0922 | 153.0914 | C7H6O4 | Protocatechuic acid |
| 6 | 7.109 | 178.0506 | 179.0349 | C15H24N2O2 | Caffeate |
| 7 | 9.003 | 463.0878 | 463.0873 | C21H20O12 | [Hyperoside](javascript:treeMenu(0)) |
| 8 | 9.271 | 303.0512 | 303.0508 | C15H10O7 | Quercetin |
| 9 | 9.832 | 464.3002 | 464.297 | C21H20O12 | Isoquercitrin |
| 10 | 10.183 | 610.3217 | 610.32 | C27H30O16 | Rutin |
| 11 | 10.452 | 594.2133 | 594.21 | C27H35O5 | Kaempferol-3-O-rutinoside |
| 12 | 10.793 | 476.3361 | 476.3364 | C21H20O11 | Astragalin |
| 13 | 12.033 | 271.0689 | 271.061 | C15H12O5 | Naringenin |
| 14 | 15.525 | 288.3132 | 288.3128 | C15H10O6 | Kaempferol |
| 15 | 17.542 | 302.3295 | 302.3287 | C14H6O8 | Ellagic acid |
| 16 | 18.413 | 194.0819 | 194.0823 | C10H10O4 | Ferulic acid |
| 17 | 20.414 | 318.325 | 318.3251 | C16H12O7 | Isorhamnetin |

RT: Real Time.